AR019131A1 - Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento - Google Patents

Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento

Info

Publication number
AR019131A1
AR019131A1 ARP990102060A ARP990102060A AR019131A1 AR 019131 A1 AR019131 A1 AR 019131A1 AR P990102060 A ARP990102060 A AR P990102060A AR P990102060 A ARP990102060 A AR P990102060A AR 019131 A1 AR019131 A1 AR 019131A1
Authority
AR
Argentina
Prior art keywords
acc
phe
aib
ala
suppressed
Prior art date
Application number
ARP990102060A
Other languages
English (en)
Original Assignee
Ns Scient S A S Societe De Conseils De Rech S Et D Applicatio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ns Scient S A S Societe De Conseils De Rech S Et D Applicatio filed Critical Ns Scient S A S Societe De Conseils De Rech S Et D Applicatio
Publication of AR019131A1 publication Critical patent/AR019131A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57563Vasoactive intestinal peptide [VIP]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)

Abstract

Análogos de polipéptidos pituitarios que activan la adenilato ciclasa, que comprende un péptido de formula: (R1R2)A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-A29-A30-A31-A32-A33-A34-A35-A36-A37-A38-R3 o una sal farmacéuticamente aceptable del mismo,donde: A1 es His o Pal; A2 es Ser, Thr o hSer; A3 es Asp o Glu; A4 es Gly, beta-Ala, Gaba, Ava, Aib, Acc o HN-(CH2)m-C(O); A5 es Ile, Leu, Cha, Nle, Val, Tle,Abu, Aib, Acc o Nva; A6 es Phe, p-X-Phe, beta-Nal, Cha, Tyr, Trp, Acc o Alb; A7 es Thr, Ser o Val; A8 es Asp o Glu; A9 es Ser, Thr o hSer; A10 es Tyr, p-X-Phe,Phe, Amp, beta-Nal, Trp o Acc; A11 es Ser, Thr o hSer; A12, A14 y A15 son seleccionados en forma independiente del grupo formado por Arg, Lys, Orn, hArg yHN-CH((CH2)n-NH-R4)-C(O); A13 es Tyr, p-X-Phe, Phe, Amp, beta-Nal, Trp o Acc; A16 es Gin, Glu, Asp o Asn; A17 es Met, Leu, Nle, Abu, Tle, Val, Ile, Cha, Ala,Aib, Acc o Nva; A18 es Ala, Aib o Acc; A19 es Val, Leu, Ile, Ala, Abu, Tle, Cha, Aib, Acc, Nle o Nva; A20, A21, A29, A30, A32, A34, A36 y A38 son cada unoindependientemente seleccionados del grupo formado por Lys, Arg, Orn, hArg y HN-CH((CH2)n-NH-R4)-C(O) o es suprimido; A22 es Tyr, p-X-Phe, Phe, Amp, beta-Nal,Trp o Acc o es suprimido; A23 es Leu, Ile, Nle, Tle, Met, Val, Ala, Aib, Acc, Cha, Phe, p-X-Phe, Abu, Nva o es suprimido; A24 es Ala, Aib, Val, Acc, Ile, Leu,Nle, Tle, Nva o es suprimido; A25 es Ala, Glu, Aib, Val, Abu, Acc, Ile, Leu, Nle, Nva o Tle essuprimido; A26 es Val,Leu,Ile,Ala, Abu, Tie, Cha, Aib, Acc, Nva,Nle o es suprimido; A27 es Leu, Ile, Nle, Tle, Met, Val, Ala, Alb, Acc, Nva, Cha, Phe, p-X-Phe, Abu o es suprimido; A28 es Gly, Aib, Acc, beta-Ala, Gaba, Ava,HN-(CH2)m-C(O) o es suprimido; A31 es Tyr, p-X-Phe, Phe, Amp, beta-Nal, Trp o Acc o es suprimido; A33 es Gln, Asn, Glu, Asp o es suprimido; A35 es Val, Leu,Ile, Ala, Abu, Tle, Cha, Aib, Nva, Acc, Nle o es suprimido; A37 es Asn, Gln, Asp, Glu, Ala, Aib, Acc o es suprimido; R1 yR2 son cada uno independientementeseleccionados del grupo formado por H, alquilo C1-30, alquenilo C2-30, fenil-alquilo C1-30, naftil-alquilo C1-30, hidroxi-alquilo C1-30, hidroxi-alquenilo
ARP990102060A 1998-07-20 1999-05-03 Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento AR019131A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11954098A 1998-07-20 1998-07-20

Publications (1)

Publication Number Publication Date
AR019131A1 true AR019131A1 (es) 2001-12-26

Family

ID=22384966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990102060A AR019131A1 (es) 1998-07-20 1999-05-03 Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento

Country Status (15)

Country Link
EP (2) EP1098906B1 (es)
JP (2) JP2002521390A (es)
AR (1) AR019131A1 (es)
AT (1) ATE449789T1 (es)
AU (1) AU3826899A (es)
CA (1) CA2335341A1 (es)
CZ (1) CZ2001253A3 (es)
DE (1) DE69941708D1 (es)
DK (1) DK1098906T3 (es)
ES (1) ES2335827T3 (es)
HU (1) HUP0104934A3 (es)
NO (1) NO20010284L (es)
PL (1) PL345583A1 (es)
TW (1) TWI221845B (es)
WO (1) WO2000005260A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972319B1 (en) 1999-09-28 2005-12-06 Bayer Pharmaceuticals Corporation Pituitary adenylate cyclase activating peptide (PACAP)receptor 3 (R3) agonists and their pharmacological methods of use
SK5552002A3 (en) * 1999-09-28 2003-05-02 Bayer Ag Pituitary adenylate cyclase activating peptide (PACAP) receptor 3 (R3) agonists and their pharmacological methods of use
JP2004500906A (ja) 1999-11-12 2004-01-15 ルーベン, レオ 電気的調節および化学的調節のための心臓デバイス、ならびに心肺障害の処置のための血管作用性腸ペプチド
WO2001060862A1 (en) * 2000-02-18 2001-08-23 Dabur Research Foundation Vasoactive intestinal peptide analogs
ATE355304T1 (de) * 2000-02-18 2006-03-15 Dabur Res Foundation Radiomarkierte vip-analoge zur diagnose und therapie
CN101229363A (zh) 2000-11-28 2008-07-30 蒙多生物技术许可股份公司 具有血管活性肠肽的生物学活性的用于治疗肺动脉和小动脉高压的化合物
JP2002293799A (ja) * 2001-03-29 2002-10-09 Itoham Foods Inc 新規ペプチド及びそれを含有する消化管運動抑制剤
US7048934B2 (en) 2001-08-30 2006-05-23 Stem Cell Therapeutics Inc. Combined regulation of neural cell production
JP4906231B2 (ja) * 2001-09-14 2012-03-28 ステム セル セラピューティクス インコーポレイテッド プロラクチン誘導性の神経幹細胞数の増加ならびにその治療用途
CA2485216A1 (en) * 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
US20060241028A1 (en) * 2002-06-10 2006-10-26 Dorian Bevec Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of sarcoidosis
CA2492442A1 (en) 2002-07-31 2004-02-05 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7615219B2 (en) 2003-01-16 2009-11-10 Life Sciences Research Partners Vzw Inhibition of PACAP signalling for the prevention and treatment of thrombocytopenia
US7846898B2 (en) 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
US7595294B2 (en) * 2004-10-08 2009-09-29 Transition Therapeutics, Inc. Vasoactive intestinal polypeptide pharmaceuticals
JP2006306770A (ja) * 2005-04-27 2006-11-09 Nidek Co Ltd 眼疾患治療剤
KR20080074108A (ko) 2005-09-27 2008-08-12 스템 셀 테라퓨틱스 코포레이션 프로락틴에 의해 조절되는 올리고덴드로사이트 전구체 세포증식
US7582608B2 (en) 2005-10-26 2009-09-01 Eli Lilly And Company Selective VPAC2 receptor peptide agonists
EP2496245B1 (en) * 2009-11-02 2016-07-20 The Administrators Of The Tulane Analogs of pitutary adenylate cyclase-activating polypeptide (pacap) and methods for their use
CA2901231C (en) * 2013-02-15 2020-06-23 Thomas Jefferson University Kit comprising lyophilized compositions for tumor imaging
EA032830B1 (ru) 2013-03-15 2019-07-31 Эмджен Инк. Антитела к pac1 человека и их применение для лечения головной боли
WO2014197909A1 (en) * 2013-06-07 2014-12-11 The Administrators Of The Tulane Educational Fund Analogs of pituitary adenylate cyclase-activating polypeptide (pacap) and methods for their use
WO2015023890A1 (en) * 2013-08-14 2015-02-19 The Arizona Board Of Regents On Behalf Of The University Of Arizona Glycosylated pacap/vip analogues with enhanced cns penetration for treatment of neurodegenerative diseases
US9989541B2 (en) 2013-12-27 2018-06-05 Dignity Health Diagnosing and treating alzheimer's disease
MX2017003247A (es) 2014-09-15 2017-11-30 Amgen Inc Proteina de union a antigenos, bi-especificos del receptor anti-cgrp/receptor pac1 y usos de las mismas.
WO2017106578A1 (en) 2015-12-15 2017-06-22 Amgen Inc. Pacap antibodies and uses thereof
US11021514B2 (en) 2016-06-01 2021-06-01 Athira Pharma, Inc. Compounds
WO2018129200A2 (en) 2017-01-05 2018-07-12 The Regents Of The University Of California Pac1 receptor agonists (maxcaps) and uses thereof
BR112020013621A2 (pt) 2018-01-12 2020-12-01 Amgen Inc. anticorpos contra pac1 e usos dos mesmos

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CS277405B6 (en) * 1986-06-12 1993-03-17 Vyzk Ustav Farm Biochem Sp Peptides with 1-amino-1-cycloalkane carboxylic acid
US5128242A (en) * 1989-06-19 1992-07-07 The Administrators Of The Tulane Educational Fund Hypothalamic polypeptides with adenylate cyclase stimulating activity
US5623050A (en) * 1991-08-22 1997-04-22 Takeda Chemical Industries, Ltd. Stable polypeptides having c-AMP production enhancing activity and the use thereof
JP3354173B2 (ja) * 1991-08-22 2002-12-09 武田薬品工業株式会社 ポリペプチドおよびその用途
JPH10505863A (ja) * 1994-09-22 1998-06-09 ジ・アドミニストレーターズ・オブ・ザ・チューレン・エデュケイショナル・ファンド 脳障害の予防および治療のための方法および医薬組成物
AU5441096A (en) * 1995-04-14 1996-10-30 The Administrators Of The Tulane Eductional Fund Analogs of growth hormone-releasing factor
US5753206A (en) * 1995-06-07 1998-05-19 Immunomedics, Inc. Radiometal-binding analogues of luteinizing hormone releasing hormone
WO1996041814A1 (fr) * 1995-06-09 1996-12-27 Itoham Foods Inc. Peptide, bronchodilatateur et agent facilitant l'ecoulement sanguin
US5955574A (en) * 1995-07-13 1999-09-21 Societe De Conseils De Recherches Et D'applications Scientifiques, S.A. Analogs of parathyroid hormone
US5723577A (en) * 1995-07-13 1998-03-03 Biomeasure Inc. Analogs of parathyroid hormone
AU6846196A (en) * 1995-08-15 1997-03-12 International Software Machines Programmable compiler

Also Published As

Publication number Publication date
NO20010284D0 (no) 2001-01-17
HUP0104934A2 (hu) 2002-04-29
CZ2001253A3 (cs) 2001-11-14
EP2161282A1 (en) 2010-03-10
TWI221845B (en) 2004-10-11
EP1098906B1 (en) 2009-11-25
JP2002521390A (ja) 2002-07-16
AU3826899A (en) 2000-02-14
DK1098906T3 (da) 2010-03-29
ES2335827T3 (es) 2010-04-05
DE69941708D1 (de) 2010-01-07
CA2335341A1 (en) 2000-02-03
EP1098906A1 (en) 2001-05-16
NO20010284L (no) 2001-03-19
PL345583A1 (en) 2001-12-17
ATE449789T1 (de) 2009-12-15
HUP0104934A3 (en) 2002-05-28
WO2000005260A1 (en) 2000-02-03
JP2010189398A (ja) 2010-09-02

Similar Documents

Publication Publication Date Title
AR019131A1 (es) Analogos de polipeptidos pituitarios que activan la adenilato ciclasa, una composicion farmaceutica que los comprende, y el uso de dichos peptidos para lamanufactura de un medicamento
KR100582510B1 (ko) 엘에이치-알에이치 단백질 효능제 또는 길항제, 이의 용도 및 이를 함유하는 약제학적 조성물
ES2329233T3 (es) Analogos de la hormona paratiroidea.
EP0301087B1 (en) Peptide
US7410948B2 (en) Analogs of parathyroid hormone
RU2001118855A (ru) Аналоги glp-1
US6544949B1 (en) Analogs of parathyroid hormone
AR073099A2 (es) Analogos de ghrelina
IL79534A0 (en) Synthetic peptides being grf analogs and pharmaceutical compositions containing them
US5955426A (en) Cyclic hexapeptide somatostatin analogues
NZ235312A (en) Human growth hormone releasing factor analogues
AR066175A1 (es) Ligandos del receptor de melanocortina de peptidos ciclicos
KR930702386A (ko) 노나펩티드 봄베신 길항제
JPS63154699A (ja) バソプレシン拮抗剤
AR043688A1 (es) Analogos del peptido yy
EP1131083B1 (en) Use of growth hormone releasing compounds and their antagonists for the treatment of tumors
Zarandi et al. Synthesis and in vitro evaluation of new potent antagonists of growth hormone-releasing hormone (GH-RH)
AR076950A2 (es) Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen
KR100321448B1 (ko) 성장호르몬저해활성이있는소마토스타틴-유사체인고리형펩티드
EP0937101B1 (en) Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them
EP1818061A1 (en) Use of ghrelin for stimulating hair growth
Mokotoff et al. Synthesis and biological evaluation of novel potent antagonists of the bombesin/gastrin releasing peptide receptor
AU768516B2 (en) Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
CZ6764U1 (cs) Peptldové analogy kuřecího GnRH II a lososího GnRH
MXPA99004512A (es) Analogos lh-rh conformacionalmente restringidos,sus usos y composiciones farmaceuticas que los contiene

Legal Events

Date Code Title Description
FA Abandonment or withdrawal